LabCorp shares 2 new hepatitis C virus drug resistance assays
The HCV NS5A and NS5B Drug Resistance Assays join HCV GenoSure NS3/4A in LabCorp's arsenal of HCV resistance tests. They are available to the public via Monogram Biosciences, which is a branch of the LabCorp Specialty Testing Group.
Chronic HCV is the main cause of liver failure and hepatocellular carcinoma. The U.S. Centers for Disease Control and Prevention estimates that more than 3 million people in the U.S. and 170 million people worldwide live with HCV infections.
Since 2011, the U.S. Food and Drug Administration (FDA) has approved six new HCV treatment applications. All involve one or more direct acting antiviral (DAA) agents, because these agents drastically improve HCV rates when compared with interferon-based treatments.
“LabCorp’s launch of the HCV NS5A and NS5B Drug Resistance Assays, combined with the first-to-market HCV GenoSure NS3/4A Assay, enables clinicians to assess resistance to all of the DAA treatment regimens that have been approved by the FDA,” Dr. Marcia Eisenberg, LabCorp Diagnostics’ chief scientific officer, said. “LabCorp’s expanded HCV drug resistance testing portfolio is the latest example of LabCorp’s commitment to deliver world-class diagnostics to reduce treatment failures and improve patient outcomes at lower costs.”